Quick Answer
Trevi Therapeutics, Inc. reported Net Income Loss of -$42.76 million for the year ending 2025.
- Trevi Therapeutics, Inc. showed an increase of +10.8% in Net Income Loss from 2024 to 2025.
- This data is from Trevi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Trevi Therapeutics, Inc.'s Net Income Loss has declined by 108.1%.
- Historical annual values: Fiscal year 2025: -$42.76 million | Fiscal year 2024: -$47.91 million | Fiscal year 2023: -$29.07 million | Fiscal year 2022: -$29.15 million | Fiscal year 2021: -$33.94 million | Fiscal year 2020: -$32.76 million | Fiscal year 2019: -$26.05 million | Fiscal year 2018: -$20.55 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: